Cooper Companies (NASDAQ:COO) Price Target Cut to $99.00 by Analysts at Needham & Company LLC

Cooper Companies (NASDAQ:COO) had its price objective lowered by investment analysts at Needham & Company LLC from $100.00 to $99.00 in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the medical device company’s stock. Needham & Company LLC’s price target suggests a potential upside of 22.75% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Wells Fargo & Company raised their price target on Cooper Companies from $72.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, December 5th. Morgan Stanley raised their target price on Cooper Companies from $76.00 to $83.00 and gave the company an “equal weight” rating in a report on Monday, December 8th. The Goldman Sachs Group restated a “sell” rating and set a $73.00 target price on shares of Cooper Companies in a research report on Friday, January 9th. Citigroup reiterated a “neutral” rating and issued a $88.00 price target (up previously from $72.00) on shares of Cooper Companies in a report on Monday, December 8th. Finally, Barclays set a $98.00 price objective on shares of Cooper Companies and gave the stock an “overweight” rating in a report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $90.77.

Cooper Companies Stock Performance

NASDAQ:COO opened at $80.65 on Tuesday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.89 and a quick ratio of 1.13. The firm has a market cap of $15.81 billion, a price-to-earnings ratio of 42.90, a price-to-earnings-growth ratio of 2.32 and a beta of 1.03. The firm’s fifty day moving average price is $81.16 and its 200 day moving average price is $74.31. Cooper Companies has a 1-year low of $61.78 and a 1-year high of $97.21.

Cooper Companies (NASDAQ:COO) last released its earnings results on Thursday, December 4th. The medical device company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.11 by $0.04. Cooper Companies had a net margin of 9.16% and a return on equity of 10.02%. The company had revenue of $1.07 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same quarter last year, the business earned $1.04 EPS. The business’s revenue was up 4.6% on a year-over-year basis. Cooper Companies has set its FY 2026 guidance at 4.450-4.600 EPS and its Q1 2026 guidance at 1.020-1.040 EPS. On average, sell-side analysts expect that Cooper Companies will post 3.98 EPS for the current year.

Insider Activity

In related news, CEO Albert G. White III purchased 10,000 shares of the business’s stock in a transaction dated Tuesday, December 16th. The stock was bought at an average cost of $80.80 per share, with a total value of $808,000.00. Following the completion of the acquisition, the chief executive officer directly owned 236,151 shares in the company, valued at $19,081,000.80. The trade was a 4.42% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius acquired 2,000 shares of Cooper Companies stock in a transaction dated Wednesday, December 17th. The stock was bought at an average price of $82.50 per share, for a total transaction of $165,000.00. Following the completion of the transaction, the director directly owned 7,777 shares of the company’s stock, valued at approximately $641,602.50. This represents a 34.62% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders acquired 16,014 shares of company stock worth $1,304,416. 1.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Buckhead Capital Management LLC raised its stake in shares of Cooper Companies by 14.3% in the 3rd quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company’s stock valued at $4,040,000 after acquiring an additional 7,368 shares during the period. First American Bank purchased a new position in Cooper Companies in the 3rd quarter worth approximately $1,646,000. Rakuten Investment Management Inc. acquired a new stake in Cooper Companies in the third quarter valued at approximately $11,341,000. Amundi lifted its position in shares of Cooper Companies by 35.5% during the second quarter. Amundi now owns 1,331,480 shares of the medical device company’s stock worth $97,225,000 after purchasing an additional 348,652 shares in the last quarter. Finally, Thompson Investment Management Inc. acquired a new position in shares of Cooper Companies during the third quarter worth $3,728,000. Institutional investors and hedge funds own 24.39% of the company’s stock.

About Cooper Companies

Cooper Companies, Inc (NASDAQ: COO) is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women’s health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.